Could a liver drug help people see color? tiny trial launched
NCT ID NCT04041232
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether an FDA-approved drug called glycerol phenylbutyrate (PBA) can improve vision in people with a rare form of color blindness caused by mutations in the ATF6 gene. Only 2 participants are enrolled, and they will take PBA three times daily while their vision is monitored with various tests. The study is currently suspended, so results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glycerol phenylbutyrate (PBA)
What this could lead to
If it works, this could point toward a treatment to improve vision in people with a rare form of color blindness caused by ATF6 mutations.
What could go wrong
This is a very early, tiny trial (only 2 participants) that is currently suspended. Even if results are positive, much larger studies would be needed to confirm any benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHROMATOPSIA 7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States